title: [Effects of drugs known to trigger psoriasis on HaCaT keratinocytes].
abstract: To investigate whether lithium carbonate, propranolol or chloroquine aggravate psoriasis through influencing cytokines of the psoriatic cytokine network, HaCaT keratinocytes were stimulated with TNF-a after treatment with these drugs. Protein secretion of a set of multiple different cytokines and growth factors in culture supernatants were measured by using a cytokine antibody array technology. Expression of IL-8 and IL-6 mRNA was determined by real-time PCR. In culture supernatants of TNF-alpha-stimulated HaCaT cells, production of IL-6 and TNF-alpha could be enhanced by lithium carbonate; production of IL-6 and a panel of cytokines and growth factors could be enhanced by propranolol hydrochloride; and IL-6 was up-regulated by chloroquine diphosphate as well. Real-time PCR analysis showed a significantly dose-dependent increase of IL-8 and IL-6 mRNA expression in HaCaT cells stimulated with TNF-a as compared to cells without TNF-alpha-stimulation, the mRNA expression of IL-8 was higher than that of IL-6 with the same concentration of TNF-alpha (P < 0.01). Compared with HaCaT cells cultured with medium alone, propranolol hydrochloride at the concentration of 1 x 10(-6) mol x L(-1) could stimulate HaCaT cells to express higher level of IL-6 mRNA (P < 0.05). The drugs investigated show a modulatory effect on certain cytokines and growth factors which are able to modulate inflammatory type of immune reaction present in psoriatic lesions.
authors.affiliation: Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
authors.forename: Jian-ping
authors.initials: JP
authors.lastname: Cen
authors.forename: Ke-jian
authors.initials: KJ
authors.lastname: Zhu
authors.forename: Na
authors.initials: N
authors.lastname: Jin
authors.forename: Ai-hua
authors.initials: AH
authors.lastname: Lin
authors.forename: Hao
authors.initials: H
authors.lastname: Cheng
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000962:Antimalarials / Q000009:adverse effects; D002478:Cells, Cultured; D002738:Chloroquine / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000235:genetics; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000235:genetics; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism*; D016651:Lithium Carbonate / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D011565:Psoriasis / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D000962:Antimalarials; D015850:Interleukin-6; D016209:Interleukin-8; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D016651:Lithium Carbonate; C023676:chloroquine diphosphate; D002738:Chloroquine; D011433:Propranolol